Cero Therapeutics Holdings, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
OQB
SCHEDULE 13D/A: Key Insider Increases Stake in CERo Therapeutics Holdings, Nearing 10% Ownership Threshold
Brian G. Atwood and the Atwood-Edminster Trust have significantly increased their beneficial ownership in CERo Therapeutics Holdings, Inc. to 9.9%, following warrant exercises and new stock option grants, while remaining below the 9.99% beneficial ownership limitation.
OQB
SCHEDULE 13D/A: Cero Therapeutics Holdings: Key Insiders Boost Stake with Nearly $1 Million Warrant Purchase
An amended Schedule 13D filing reveals that key insiders, including Brian G. Atwood and Lynne H. Edminster, have increased their potential ownership in Cero Therapeutics Holdings, Inc. through a significant warrant purchase totaling nearly $1 million.